News

Published on 29 Apr 2024 on Zacks via Yahoo Finance

What's in the Cards for Amgen (AMGN) This Earnings Season?


Article preview image

Amgen AMGN will report first-quarter 2024 results on May 2, before market open. In the last reported quarter, the company beat earnings expectations by 1.07%.

Factors to Consider

Amgen’s product sales are expected to be the lowest in the first quarter per historical trends due to the impact of benefit plan changes, insurance re-verification and increased co-pay expenses as U.S. patients work through deductibles. First-quarter 2024 total revenues are expected to grow roughly 20% year over year. The Zacks Consensus Estimate for total revenues is $7.38 billion.

NASDAQ.EXEL price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Exelixis's SWOT analysis: cabozantinib drives growth as stock faces ip...

Exelixis, Inc. (NASDAQ:EXEL), a biotechnology company specializing in the development and...

Investing.com 15 Jan 2025

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and...

Estimates for 2024 loss per share have narrowed to 96 cents from $1.29 in the past 90 days....

Zacks · via Yahoo Finance 15 Jan 2025

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with t...

Zacks · via Yahoo Finance 13 Jan 2025

Exelixis Provides Preliminary 2024 Results and Outlook for 2025

This is the third stock repurchase program undertaken by Exelixis since March 2023. Under this...

Zacks · via Yahoo Finance 13 Jan 2025

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

Exelixis, Inc. EXEL announced that the FDA has notified it about an update to its supplemental ne...

Zacks · via Yahoo Finance 11 Jan 2025

Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabomety...

Zacks · via Yahoo Finance 7 Jan 2025

Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024?

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we...

Insider Monkey · via Yahoo Finance 23 Dec 2024

Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

Quote Some better-ranked drugmakers are Novartis NVS, Gilead GILD and Exelixis EXEL, with a Zacks...

Zacks · via Yahoo Finance 18 Dec 2024

Top Research Reports for JPMorgan Chase, UnitedHealth & Verizon

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase...

Zacks · via Yahoo Finance 16 Dec 2024

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Utilizing ratios like P/E, PEG, Price/Sales...Flow, the Value Style Score identifies the most...

Zacks · via Yahoo Finance 25 Nov 2024